A novel metabolite-interacting protein(MIP)-based molecular subtyping construction and validation of IGFBP3 as a MiP-related oncogene in colorectal cancer  

作　　者：Simeng Bao Yongmin Li Yu Liang Jianxun Dai Huolin Huang Bin Ma 

机构地区：[1]Central Laboratory,Cancer Hospital of China Medical University,Cancer Hospital of Dalian University of Technology,Liaoning Cancer Hospital&Institute,Shenyang,Liaoning 110042,China [2]Department of Colorectal Surgery,Cancer Hospital of China Medical University,Cancer Hospital of Dalian University of Technology,Liaoning Cancer Hospital&Institute,Shenyang,Liaoning 110042,China [3]School of Optoelectronic Engineering and Instrumentation Science,Dalian University of Technology,Dalian,Liaoning 116024,China [4]The Liaoning Provincial Key Laboratory of Interdisciplinary Research on Gastrointestinal Tumor Combining Medicine with Engineering,Shenyang,Liaoning 110042,China

出　　处：《Genes & Diseases》2025年第2期7-10,共4页基因与疾病(英文)

基　　金：supported by grants from the Cultivation Program of National Science Foundation of Liaoning Cancer Hospital (China) (No.2021-ZLLH-03);Beijing Xisike Clinical Oncology Research Foundation (China) (No.Y-QL202101-0039);Medical and Industrial Cross Joint Fund of Dalian University of Technology-Liaoning Cancer Hospital (China) (No.LD2023027);The National Natural Science Foundation of China (No.82303131);the Liaoning Province Science and Technology Plan Joint Program (Applied Basic Research Project) (China) (No.2023JH2/101700150).

摘　　要：For prognosis and therapeutic response,colorectal cancer(CRC)patients are highly variable across stages,correlated to high inter-tumor heterogeneity at the molecular level.1 Therefore,molecular subtyping needs to be determined for stratifying patients into distinct prognostic subgroups according to tumor biology.

关 键 词：colorectal cancer IGFBP3 

分 类 号：R73[医药卫生—肿瘤]